SEC Form 6-K filed by Opthea Limited

$OPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $OPT alert in real time by email
6-K 1 opt_commercial_day.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File No. 001-39621

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

Level 4

650 Chapel Street

South Yarra, Victoria, 3141

Australia

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

 

 

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit

 

Description

99.1

 

Press Release - Opthea Investor Day

 

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

OPTHEA LIMITED

 

(Registrant)

 

 

 

 

By:

/s/ Frederic Guerard

 

Name:

Frederic Guerard

 

Title:

Chief Executive Officer

 

Date: 01/28/2025

 


Get the next $OPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPT

DatePrice TargetRatingAnalyst
12/8/2022$14.00Buy
H.C. Wainwright
4/26/2022$25.00Outperform
SVB Leerink
More analyst ratings

$OPT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Opthea Completes COAST Final Week 52 Patient Visit

    COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25 MELBOURNE, Australia and PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Opthea to Present at Oppenheimer Healthcare Conference

    MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceDate:February 11-12, 2025Presentation:   Tuesday, February 11, 2025, 10:00 AM ETWebcast Li

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Opthea Wet AMD Data Featured at Macula Society Meeting

    MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held   February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. Details are as follows: Session:Neovascular AMD I: Trials  Timing:Friday, February 14, 2025, 8:0

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$OPT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OPT
SEC Filings

See more

$OPT
Leadership Updates

Live Leadership Updates

See more
  • Opthea Appoints Kathy Connell to Board of Directors

    Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

    Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

    MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$OPT
Financials

Live finance-specific insights

See more
  • Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

    MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$OPT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more